NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

If you are using the table in the DD trial to help you judge the curve to arrive at those data points, it is important to know that your data points are from the time of registration using the table 2, but time from completion of chemoradiation if using the curves. In other words, your median OS for the whole group should be closer to 15.5 mOS if referring to time from random assignment (as opposed to the 17 months you have). Your 2 year survival from random assignment would be closer to 31%, as opposed the 35% you have, imo.

Just remember the time from randomization in the dd trial is about two months shorter than the time from registration within the dd trial.

(The UCLA chart someone referred to is from time of diagnosis)

(The Optune, Celdex, IMUC and DCVax-L trials measure from the shorter of the two measurements above -- from time of randomization.)

(One very interesting thing of note to me is that the 21 month mark from last randomization (for DCVax-L Aug 5, 2017) is also the 24 month mark from last DCVax-L screening recruitment. The interesting part is this is also the mark to beat Optune mOS. In other words, each and every patient placed in the DCVax-L trial has a chance to possibly move DCVax-L's PFS and/or OS treatment median beyond Optune's mOS 20.9 months from randomization if DCVax-L's trial data cutoff is around August 5th or later -- if the DCVax-L trial is doing well.)